NovaTarg Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
NovaTarg is a drug discovery and development organization focused on new medicines to treat metabolic diseases and cancer. Innovative agents for Polycystic Kidney Disease (PKD) and Type 2 Diabetes (T2D) have been identified and are in early development for these indications.
NT1238 is a kidney selective AMPK activator with efficacy in mouse models of PKD. It has an excellent PK profile including good exposure in kidney and with very low drug elimination in urine. This is an ideal profile for a drug to treat PKD and is the first drug designed specifically for this purpose.
NT1195 is a novel biguanide which we have selected for the treatment of T2D in patients with kidney disease. NT1195 demonstrates the desired pharmacologic profile for a diabetes therapy, has great PK properties and is not renally cleared. This property allows treatment of all T2D patients including those with impaired renal function.
NovaTarg seeks partners to assist in the early development of NT1238 and NT1195.
Company Type:
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Lead Product in Development:
NT1238
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
NovaTarg Therapeutics